MMP9 and hypercalcemia disease: Zoledronate, another drug used to treat hypercalcemia, suppresses MMP-2 and MMP-9 expression in PC3 prostate cancer cells, indicating that it is involved in the Ras/Raf/ERK and PI3K/AKT pathways, in addition to Discoin Domain Receptors (DDR) signaling [63].